LITTLE FALLS, N.J., April 25, 2012 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today the appointment of Seth M. Yellin as Vice President of Corporate Development. Mr. Yellin will lead Cantel's active acquisition program and be heavily involved in strategic planning.
Mr. Yellin, 37, has been a healthcare industry analyst and investment professional for over ten years. Most recently, he was responsible for equity investment coverage of the medical device and life science tools industries at Citadel Asset Management. Previously he was an M&A specialist at UBS Investment Bank. Mr. Yellin received a BA from Princeton University and an MBA from The Wharton School at the University of Pennsylvania.
"Seth's experience as a healthcare investor and investment banker brings a valuable skill set to our organization and makes him well qualified to direct Cantel's acquisition program and other corporate development activities," said Andrew Krakauer, President and CEO of Cantel Medical.
Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
SOURCE Cantel Medical Corp.